- Home
- QIPT vs ABOS Comparison
QIPT vs ABOS Comparison
Compare QIPT & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- ABOS
- Stock Information
- Founded
- QIPT 1993
- ABOS 1996
- Country
- QIPT United States
- ABOS United States
- Employees
- QIPT N/A
- ABOS N/A
- Industry
- QIPT
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- ABOS Health Care
- Exchange
- QIPT Nasdaq
- ABOS Nasdaq
- Market Cap
- QIPT 104.7M
- ABOS 109.6M
- IPO Year
- QIPT N/A
- ABOS 2021
- Fundamental
- Price
- QIPT $2.41
- ABOS $2.02
- Analyst Decision
- QIPT Buy
- ABOS Strong Buy
- Analyst Count
- QIPT 2
- ABOS 3
- Target Price
- QIPT $3.15
- ABOS $7.67
- AVG Volume (30 Days)
- QIPT 278.0K
- ABOS 184.9K
- Earning Date
- QIPT 12-15-2025
- ABOS 11-12-2025
- Dividend Yield
- QIPT N/A
- ABOS N/A
- EPS Growth
- QIPT N/A
- ABOS N/A
- EPS
- QIPT N/A
- ABOS N/A
- Revenue
- QIPT $238,378,000.00
- ABOS N/A
- Revenue This Year
- QIPT N/A
- ABOS N/A
- Revenue Next Year
- QIPT $28.69
- ABOS N/A
- P/E Ratio
- QIPT N/A
- ABOS N/A
- Revenue Growth
- QIPT N/A
- ABOS N/A
- 52 Week Low
- QIPT $1.35
- ABOS $0.86
- 52 Week High
- QIPT $3.27
- ABOS $2.46
- Technical
- Relative Strength Index (RSI)
- QIPT 52.68
- ABOS 55.48
- Support Level
- QIPT $2.15
- ABOS $1.51
- Resistance Level
- QIPT $2.39
- ABOS $1.72
- Average True Range (ATR)
- QIPT 0.11
- ABOS 0.16
- MACD
- QIPT 0.01
- ABOS 0.00
- Stochastic Oscillator
- QIPT 76.12
- ABOS 87.04
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.